How Adrenomedullin Drives the Shift From Compensated to Decompensated Septic Shock
Adrenomedullin plays a central role in both the early beneficial vasodilation and the late dangerous cardiovascular collapse of sepsis, making it both a therapeutic target and a biomarker for sepsis progression.
Quick Facts
What This Study Found
Adrenomedullin contributes to both phases of sepsis: beneficial vasodilation during early compensation and harmful cardiovascular collapse during late decompensation, driven by progressive ADM accumulation from reduced clearance and increased tissue production.
Key Numbers
How They Did This
Review synthesizing data on adrenomedullin dynamics during experimental sepsis, covering tissue production, pulmonary clearance, receptor regulation, and hemodynamic effects across both sepsis phases.
Why This Research Matters
Understanding the dual role of ADM in sepsis — helpful early, harmful late — could guide timing of potential ADM-modulating therapies to preserve early benefits while preventing late collapse.
The Bigger Picture
Sepsis kills more people than many cancers. Understanding which peptide changes drive the transition from compensated to decompensated shock could enable therapies that prevent this deadly transition.
What This Study Doesn't Tell Us
Review based largely on animal sepsis models. The exact tipping point where ADM shifts from beneficial to harmful is not precisely defined.
Questions This Raises
- ?Can ADM levels be used to time therapeutic intervention in sepsis?
- ?Would ADM receptor antagonists help in late sepsis without harming early compensation?
- ?Could monitoring ADM predict which sepsis patients will decompensate?
Trust & Context
- Key Stat:
- Dual-phase role ADM helps in early sepsis but kills in late sepsis — the same peptide goes from friend to foe as clearance fails and accumulation grows
- Evidence Grade:
- Moderate evidence from a review integrating multiple experimental sepsis studies with coherent mechanistic framework.
- Study Age:
- Published in 2001. ADM-targeting therapies (adrecizumab) are now in clinical trials for sepsis, and MR-proADM is a clinical sepsis biomarker.
- Original Title:
- The role of adrenomedullin in producing differential hemodynamic responses during sepsis.
- Published In:
- The Journal of surgical research, 95(2), 207-18 (2001)
- Authors:
- Koo, D J, Zhou, M(3), Chaudry, I H(4), Wang, P
- Database ID:
- RPEP-00672
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why does sepsis worsen suddenly?
The body's own vasodilator peptide adrenomedullin initially helps by maintaining blood flow. But as sepsis worsens, the lungs can't clear ADM fast enough, it accumulates, and blood pressure collapses — the same peptide becomes lethal.
Can this be treated?
ADM-targeting drugs (like adrecizumab) are being tested for sepsis. The key is timing — intervening before ADM accumulation causes irreversible cardiovascular collapse.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00672APA
Koo, D J; Zhou, M; Chaudry, I H; Wang, P. (2001). The role of adrenomedullin in producing differential hemodynamic responses during sepsis.. The Journal of surgical research, 95(2), 207-18.
MLA
Koo, D J, et al. "The role of adrenomedullin in producing differential hemodynamic responses during sepsis.." The Journal of surgical research, 2001.
RethinkPeptides
RethinkPeptides Research Database. "The role of adrenomedullin in producing differential hemodyn..." RPEP-00672. Retrieved from https://rethinkpeptides.com/research/koo-2001-the-role-of-adrenomedullin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.